Annotation Detail

Information
Associated Genes
ERBB2
Associated Variants
ERBB2 AMPLIFICATION ( ENST00000269571.10 )
ERBB2 AMPLIFICATION ( ENST00000269571.10 )
Associated Disease
stomach cancer
Source Database
CIViC Evidence
Description
In a phase 1 trial, patients with HER2-positive gastric cancer were treated with Trastuzumab Deruxtecan (DS-8201a). The response rate was 43.2% (19/44).
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/7647
Gene URL
https://civic.genome.wustl.edu/links/genes/20
Variant URL
https://civic.genome.wustl.edu/links/variants/306
Rating
4
Evidence Type
Predictive
Disease
Stomach Cancer
Evidence Direction
Supports
Drug
Trastuzumab Deruxtecan
Evidence Level
B
Clinical Significance
Sensitivity/Response
Pubmed
31047804
Drugs
Drug NameSensitivitySupported
Trastuzumab DeruxtecanSensitivitytrue